<DOC>
	<DOCNO>NCT01566643</DOCNO>
	<brief_summary>This prospective control randomized open-label clinical trial design determine optimal eradication rate rabeprazole base sequential-concommitant hybrid therapy adult infect Helicobacter pylori Eastern Taiwan . Enrolled patient receive 3 , 5 7 day pre-concommitant ( sequential part ) treatment rabeprazole + amoxicillin , 7 day concommitant treatment rabeprazole + amoxicillin + clarithromycin + metronidazole .</brief_summary>
	<brief_title>Rabeprazole Based Sequential-Concommitant Hybrid Therapies H. Pylori Infections</brief_title>
	<detailed_description>Background : Antimicrobial resistance decrease worldwide eradication rate common used triple therapy Helicobacter pylorus infection ( le 80 % ) . Objective : To determine optimal pre-concommitant treatment length rabeprazole base sequential-concomitant hybrid therapy adult infect Helicobacter pylori Eastern Taiwan . Design : Randomized , open-label , prospective control trial . Patients : 231 patient dyspepsia peptic ulcer infect Helicobacter pylorus . Measurements : 13C-urea breath test , upper endoscopy , histologic evaluation , rapid urease test , bacterial culture , assessment antibiotic resistance CYP2C19 genotype host . Intervention : 231 patient Helicobacter pylori infection recruit randomly assign receive one follow therapeutic scheme : group 1 , 14-days hybrid therapy : rabeprazole 20mg bid + amoxicillin 1g bid treat 7 day , rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid 7 day ; group 2 , 12-days hybrid therapy : rabeprazole 20mg bid + amoxicillin 1g bid treat 5 day , rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid 7 day ; group 3 , 10-days hybrid therapy : rabeprazole 20mg bid + amoxicillin 1g bid treat 3 day , rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid 7 day . Repeat upper endoscopy histologic evaluation , rapid urease test 13C-urea breath test 4 week treatment ass treatment result . The influence hybrid therapy antibiotic resistance Helicobacter pylorus CYP2C19 genotype host determine . Expected result : The rabeprazole base sequential-concomitant therapy eradication Helicobacter pylorus effective , outcome affect antibiotic resistance Helicobacter pylorus CYP2C19 genotype host .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patient prove infection H. pylori gastric mucosa ( least two four test positive ) woman breast feeding pregnancy . allergy drug use study . previously treat H. pylorus . intolerance fructose , lactose . patient hematologic , brain spinal disorder patient 20 year old patient aspirin clopidogrel patient history gastric cancer gastric resection operation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>antibiotic resistance</keyword>
	<keyword>sequential-concomitant hybrid therapy</keyword>
</DOC>